CompletedPHASE1, PHASE2NCT02956746

A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines

Studying Rabies

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Synermore Biologics Co., Ltd.
Principal Investigator
Wyatt J David, PhD
inVentiv Health Clinical Research Services LLC
Intervention
SYN023(biological)
Enrollment
164 target
Eligibility
18-50 years · All sexes
Timeline
20162018

Study locations (1)

Collaborators

inVentiv Health Clinical

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02956746 on ClinicalTrials.gov

Other trials for Rabies

Additional recruiting or active studies for the same condition.

See all trials for Rabies

← Back to all trials